Researchers report that COVID antiviral treatments are working less well in populations with high levels of vaccination and prior infection immunity. The new analysis suggests the real-world benefit is smaller than earlier estimates, as immune protection from past vaccination or infection reduces the pool of patients who would otherwise benefit most from antivirals.
The Conversation and Business Line both highlight the same central finding: widespread immunity changes the baseline risk of severe disease, so measured antiviral effectiveness declines. The outlets focus on how this shift affects interpretation of clinical results over time, implying that antiviral impact may depend on the immunity level in a given community. While the reporting aligns on the conclusion that antivirals remain a tool for treating COVID, it also emphasizes that their relative effectiveness appears to have diminished compared with earlier phases of the pandemic.
Overall, the sources present the research as context-dependent: as immunity increases, the incremental benefit from antivirals can look smaller when compared with earlier periods.
